Back
AbbVie, Inc. 10K Form
Buy
62
ABBV
AbbVie, Inc.
Last Price:
$223.73
Seasonality Move:
5.27%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | ABBV/AbbVie, Inc. Quarterly |
| 2023-11-06 | 10Q | ABBV/AbbVie, Inc. Quarterly |
| 2023-08-07 | 10Q | ABBV/AbbVie, Inc. Quarterly |
| 2023-05-05 | 10Q | ABBV/AbbVie, Inc. Quarterly |
| 2022-11-04 | 10Q | ABBV/AbbVie, Inc. Quarterly |
| 2022-08-04 | 10Q | ABBV/AbbVie, Inc. Quarterly |
Receive ABBV News And Ratings
See the #1 stock for the next 7 days that we like better than ABBV
ABBV Financial Statistics
Sales & Book Value
| Annual Sales: | $61.2B |
|---|---|
| Cash Flow: | $6.6B |
| Price / Cash Flow: | 19.53 |
| Annual Sales: | $-1.49 |
| Price / Book: | 247.77 |
Profitability
| EPS (TTM): | 2.36710 |
|---|---|
| Net Income (TTM): | $4.2B |
| Gross Margin: | $51.2B |
| Return on Equity: | 144.3% |
| Return on Assets: | 3.1% |
AbbVie, Inc. Earnings Forecast
Key AbbVie, Inc. Financial Ratios
-
The Gross Profit Margin over the past 17 years for ABBV is 83.71%.
-
The Selling, General & Administrative Expenses for ABBV have been equal to 22.91% of Gross Profit Margin.
-
The Research & Development expenses have been 14.73% of Revenue.
-
The Interest Expense is 62.06% of Operating Income.
-
The Net Earning history of ABBV is 6.92% of Total Revenues.
-
Per Share Earnings over the last 17 years have been positive in 7 years.
AbbVie, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ABBV |
| CUSIP: | 00287Y |
| Website: | abbvie.com |
Debt
| Debt-to-Equity Ratio: | -26.02 |
|---|---|
| Current Ratio: | 0.72 |
| Quick Ratio: | 0.47 |
Price-to-Earnings
| Trailing P/E Ratio: | 93.74 |
|---|---|
| Forward P/E Ratio: | 13.97 |
ABBV Technical Analysis vs Fundamental Analysis
Buy
62
AbbVie, Inc. (ABBV)
is a Buy
Is AbbVie, Inc. a Buy or a Sell?
-
AbbVie, Inc. stock is rated a BuyThe current AbbVie, Inc. [ABBV] share price is $223.43. The Score for ABBV is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.